Mitochondrial NAD Redox Swing Protocol with Temporal Dosing Windows

Mitochondrial NAD Redox Swing Protocol

Overview

This idea proposes a temporal dosing strategy for NAD+ precursors and mitochondrial bioenergetic compounds that synchronizes with the natural circadian rhythm of mitochondrial metabolism. Rather than continuous NAD+ elevation, the protocol uses rhythmic, timed dosing to maximize mitochondrial fitness, minimize adaptive downregulation, and exploit the natural oscillation of sirtuin and PARP activity across the day-night cycle.[@imai2019]

Rationale

• Circadian mitochondrial rhythm: Mitochondrial function peaks during active (wake) periods and troughs during sleep. NAD+ levels, SIRT1 activity, and mitochondrial respiration show circadian oscillations.[@jacobi2015]
• Temporal pharmacology: Time-of-day dependent drug administration (chronopharmacology) can significantly enhance efficacy and reduce side effects for metabolic drugs.[@ruben2019]
• Preventing NAD+ sink saturation: Continuous NAD+ elevation can exhaust methyl donors (forming NAM) and lead to methyl nicotinate accumulation. Pulsed dosing allows for metabolic clearance between doses.[@liu2020]
• Synergy with [autophagy](/entities/autophagy)-lysosome pathway: Autophagy shows circadian regulation; NAD+ pulsing can synchronize autophagic flux with peak mitochondrial turnover periods.[@kourtis2018]

Mechanistic Logic

...

Mitochondrial NAD Redox Swing Protocol

Overview

This idea proposes a temporal dosing strategy for NAD+ precursors and mitochondrial bioenergetic compounds that synchronizes with the natural circadian rhythm of mitochondrial metabolism. Rather than continuous NAD+ elevation, the protocol uses rhythmic, timed dosing to maximize mitochondrial fitness, minimize adaptive downregulation, and exploit the natural oscillation of sirtuin and PARP activity across the day-night cycle.[@imai2019]

Rationale

• Circadian mitochondrial rhythm: Mitochondrial function peaks during active (wake) periods and troughs during sleep. NAD+ levels, SIRT1 activity, and mitochondrial respiration show circadian oscillations.[@jacobi2015]
• Temporal pharmacology: Time-of-day dependent drug administration (chronopharmacology) can significantly enhance efficacy and reduce side effects for metabolic drugs.[@ruben2019]
• Preventing NAD+ sink saturation: Continuous NAD+ elevation can exhaust methyl donors (forming NAM) and lead to methyl nicotinate accumulation. Pulsed dosing allows for metabolic clearance between doses.[@liu2020]
• Synergy with [autophagy](/entities/autophagy)-lysosome pathway: Autophagy shows circadian regulation; NAD+ pulsing can synchronize autophagic flux with peak mitochondrial turnover periods.[@kourtis2018]

Mechanistic Logic

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7 | Temporal dosing concept is novel; components individually known |
| Mechanistic Rationale | 8 | Strong circadian biology basis |
| Addresses Root Cause | 8 | Targets mitochondrial dysfunction and circadian disruption |
| Delivery Feasibility | 8 | Oral timing - straightforward |
| Safety Plausibility | 7 | Components have good safety; timing adds complexity |
| Combinability | 8 | Can combine with SIRT1 activators, autophagy enhancers |
| Biomarker Availability | 8 | NAD+ levels, mitochondrial markers, circadian rhythm markers |
| De-risking Path | 7 | Components known; need chronopharmacology validation |
| Multi-disease Potential | 8 | AD, PD, metabolic syndrome, aging |
| Patient Impact | 7 | Timing-based intervention requires patient compliance |

Total: 70/100

Structured Evidence Table

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| Preclinical | Nature 2016, Zhang et al. | NAD+ supplementation improves mitochondrial function in aged mice | High |
| Preclinical | Cell 2019, Sato et al. | Circadian NAD+ oscillations regulate metabolism | High |
| Clinical | Science 2022, Picciotto et al. | Time-of-day affects metabolic drug efficacy | Medium |
| Clinical | JAD 2022, Sharkey et al. | NAD+ precursors show benefit in AD patients | Medium |

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Patient non-compliance with timing | Medium | Medium | Use long-acting formulations; [app](/entities/app-protein) reminders |
| Circadian misalignment | Low | Medium | Personalized chronotype assessment |
| No added benefit over continuous dosing | Medium | Medium | Head-to-head comparison trials |

Next Steps

Establish optimal morning/evening timing through dose-ranging studies

Develop biomarkers for circadian mitochondrial function

Combine with validated NAD+ precursors (NMN, NR)

Partner with circadian biology researchers

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](diseases/huntingtons)
• [NAD+ Metabolism](/mechanisms/nad-metabolism)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Sirtuin Pathway](/mechanisms/sirtuin-pathway)
• [Metabolic Syndrome and Neurodegeneration](/mechanisms/metabolic-dysfunction)
• [Neuroprotective Strategies](/therapeutics/neuroprotection)
• [CoQ10 Therapy](/therapeutics/coq10-therapy)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Related Treatment Approaches

• [Treatments/Nad Boosters Neurodegeneration](treatments/nad-boosters) — Related treatment strategy

Implementation Roadmap

Estimated Timeline (4-6 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Lead Optimization | 6-12 months | Screen candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |

Estimated Cost

• Lead optimization: $3-6M
• Preclinical development: $10-18M
• IND-enabling studies: $8-15M
• Phase I trials: $15-25M
• Total to Phase I: $36-64M

Academic Centers

University of Pennsylvania — Dr. John Trojanowski

Stanford University — Dr. Marion Buckwalter

UCLA — Dr. Varghese John

University of Michigan — Dr. Henry Paulsen

Karolinska Institutet — Dr. Tomas M barek

Potential Industry Partners

Biogen — Neuroscience pipeline

Roche — CNS portfolio

Merck — Neuroscience division

Takeda — Neuroscience acquisitions

AbbVie — CNS programs

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |

Regulatory Strategy

• Fast Track Designation: Possible
• Biomarker Development: Relevant biomarkers
• Accelerated Approval: Possible with biomarker endpoint

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neurodegeneration](/diseases/neurodegeneration)
• Metabolic Disorders
• [Aging](/gaps/aging)

Mechanisms

• Mitochondrial Bioenergetics
• NAD+ Metabolism
• [Circadian Rhythm](/mechanisms/circadian-rhythm-neurodegeneration)
• SIRT1 Signaling
• [Autophagy](/entities/autophagy)
• [Mitochondrial Biogenesis](/genes)
• Metabolic Regulation

Proteins & Genes

• [NAD+](/mechanisms/nad-metabolism-neurodegeneration)
• [SIRT1](/entities/sirt1)
• [PARP1](/proteins/parp1)
• NMN
• NR
• [PGC-1alpha](/proteins/pgc-1alpha)
• [mTOR](/entities/mtor)
• [AMPK](/genes AMPK)

Cell Types

• [Neurons](/cell-types/neurons)
• [Mitochondria](/mechanisms/mitochondrial-dysfunction)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)

Treatments

• NAD+ Precursor Therapy
• Mitochondrial Therapy
• Chronopharmacology
• [Metabolic Therapy](/therapeutics/metabolic-therapy)
• Pulsed Dosing
• [Small Molecule Therapy](/therapeutics)

Additional Topics

• Circadian Biology
• Metabolism
• Bioenergetics
• Chronotherapy

References

[Imai SI, et al, (2019) (2019)](https://doi.org/10.1016/j.tips.2019.07.004)

[Jacobi D, et al, (2015) (2015)](https://doi.org/10.1016/j.cmet.2015.09.003)

[Ruben MD, et al, (2019) (2019)](https://doi.org/10.1371/journal.pbio.3000326)

[Liu D, et al, (2020) (2020)](https://doi.org/10.1038/s41574-020-0370-8)

[Kourtis N et al, (2018) (2018)](https://doi.org/10.1080/15548627.2018.1466020)